Endometrial hyperplasia and neoplasia. Cytologic screening with the Endopap endometrial sampler.
A new endometrial sampling device, the Endopap, was tested in a series of 851 patients. This sampler is of simple design, without moving parts, inexpensive and easy to use. Cellular samples proved adequate in 90% of the cases, usually with very abundant material. Endometrial cancer shed atypical cells in all 20 cases studied. However, only about half the patients with adenomatous hyperplasia were correctly identified by the endometrial sample. This fact seems to reflect the lack of adequate morphologic criteria for the recognition of endometrial hyperplasia; this situation prevails with all types of endometrial cell samplers.
D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D004714:Endometrial Hyperplasia / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D004867:Equipment Design; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000295:instrumentation*; D015203:Reproducibility of Results; D014626:Vaginal Smears / Q000191:economics / Q000295:instrumentation*